Skip to main
IMMP

Immutep Ltd (IMMP) Stock Forecast & Price Target

Immutep Ltd (IMMP) Analyst Ratings

Based on 2 analyst ratings
Hold
Strong Buy 0%
Buy 50%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Immutep is in a strong financial position, with significant cash resources to conduct clinical trials and further develop its pipeline. The company is also pursuing partnerships and collaborations to advance its products and technology. With its unique approach and promising clinical data, Immutep has the potential for significant market success and may become a leading player in the immuno-oncology space.

Bears say

Immutep is heavily dependent on the success of its product candidate, eftilagimod alfa, for the company's future growth. However, the lack of diversity in its product portfolio raises concerns about its sustainability in the long term. Moreover, the high costs associated with developing and marketing a new drug could significantly impact the company's financial stability and viability in the market. Additionally, the competitive landscape in the immunotherapy market is intense, which could make it difficult for Immutep to stand out and gain market share.. Based on the company's heavy reliance on eftilagimod alfa and the potential challenges it may face in the highly competitive immunotherapy market, it is likely that Immutep's stock will face significant volatility and may struggle to maintain a stable growth trajectory. While the projected market value for efti in first-line non-small cell lung cancer is promising, further data is needed to fully assess its efficacy and potential in other types of cancer. Additionally, the high costs associated with drug development and marketing may also hinder the company's financial stability and growth potential.

Immutep Ltd (IMMP) has been analyzed by 2 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 50% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immutep Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immutep Ltd (IMMP) Forecast

Analysts have given Immutep Ltd (IMMP) a Hold based on their latest research and market trends.

According to 2 analysts, Immutep Ltd (IMMP) has a Hold consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immutep Ltd (IMMP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.